drugset / Trial / NCT00437125

Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease

NCT00437125

Phase 4 Completed 151 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

This study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with Parkinson's disease during 12 weeks treatment.

Timeline

Start
2007-03
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral